The relationship between clinical efficacy and efficacy as measured by two versions of the Continuous Performance Test of OROS-Methylphenidate in adults with ADHD: a double blind placebo controlled medication trial. - CPT and OROS-Mph in adults with ADHD

Parnassia (Den Haag)0 个研究点目标入组 44 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•ADHD-combined subtype has been diagnosed according to regular clinical diagnostic procedures
•Patient is able to read and understand Patient Information
•Patient has signed Informed Consent Form
•Patient is able and willing to fill out questionnaires
•Patient is able and willing to meet follow up appointments for the study

•- Comorbid disorder (Axis I) that is very severe at intake and that may interfere with need of rapid treatment or with the goals of the study:
•Severe current substance abuse or substance dependence (alcohol: more than 2 consumptions per day or for women more than 15 consumptions in total per week or for men more than 21 conusmptions in total per week. Cannabis: more than one joint per day. Hard drugs: exclusion per se);Anxiety and/or mood disorders will be treated with SSRIs before treatment for ADHD starts.;- Use of the following medications within a month prior to participation to the study: stimulants, anti-psychotic medication, clonidine, benzodiazepines, beta-blockers;- Symptoms of dementia, amnestic disorders or other cognitive disorders;- Symptoms of serious Cluster B Axis II psychopathology that may interfere with cooperation to the study;- For women: pregnancy, breastfeeding of lack of suitable contraception;- Mental retardation;- Insufficient fluency in the Dutch language

发起方

Parnassia (Den Haag)